BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 35800375)

  • 1. Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication.
    Hansen Q; Bachas C; Smit L; Cloos J
    Cancer Drug Resist; 2022; 5(2):344-367. PubMed ID: 35800375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference?
    Martiáñez Canales T; de Leeuw DC; Vermue E; Ossenkoppele GJ; Smit L
    Cancers (Basel); 2017 Jun; 9(7):. PubMed ID: 28665351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia.
    Sachs K; Sarver AL; Noble-Orcutt KE; LaRue RS; Antony ML; Chang D; Lee Y; Navis CM; Hillesheim AL; Nykaza IR; Ha NA; Hansen CJ; Karadag FK; Bergerson RJ; Verneris MR; Meredith MM; Schomaker ML; Linden MA; Myers CL; Largaespada DA; Sachs Z
    Cancer Res; 2020 Feb; 80(3):458-470. PubMed ID: 31784425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Progress in the leukemic stem cell study and a novel therapeutic approach targeting leukemic stem cells].
    Kikushige Y; Miyamoto T; Akashi K
    Rinsho Ketsueki; 2017; 58(10):1838-1843. PubMed ID: 28978822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: From biology to therapeutic targeting.
    Chen Y; Li J; Xu L; Găman MA; Zou Z
    Cell Death Discov; 2022 Sep; 8(1):397. PubMed ID: 36163119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targeting of leukemia stem cells in acute myeloid leukemia.
    Barbosa K; Deshpande AJ
    Front Oncol; 2023; 13():1204895. PubMed ID: 37601659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia.
    Kikushige Y; Miyamoto T
    Oncology; 2015; 89 Suppl 1():28-32. PubMed ID: 26551150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipids and the cancer stemness regulatory system in acute myeloid leukemia.
    Lim INX; Nagree MS; Xie SZ
    Essays Biochem; 2022 Sep; 66(4):333-344. PubMed ID: 35996953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical roles of TIM-3 in myeloid malignancies and its importance in cellular therapy.
    Kikushige Y
    Blood Cell Ther; 2022 Dec; 5(Spec Edition):S1-S5. PubMed ID: 37220607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1.
    Darwish NH; Sudha T; Godugu K; Elbaz O; Abdelghaffar HA; Hassan EE; Mousa SA
    Oncotarget; 2016 Sep; 7(36):57811-57820. PubMed ID: 27506934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia.
    Liu Y; Wang G; Zhang J; Chen X; Xu H; Heng G; Chen J; Zhao Y; Li J; Ni Y; Zhang Y; Shan J; Qian C
    Stem Cell Res Ther; 2021 Jan; 12(1):86. PubMed ID: 33494824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloid leukemia: therapeutic targeting of stem cells.
    Pabon CM; Abbas HA; Konopleva M
    Expert Opin Ther Targets; 2022 Jun; 26(6):547-556. PubMed ID: 35634856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal Hematopoiesis.
    Verhagen HJMP; van Gils N; Martiañez T; van Rhenen A; Rutten A; Denkers F; de Leeuw DC; Smit MA; Tsui ML; de Vos Klootwijk LLE; Menezes RX; Çil M; Roemer MGM; Vermue E; Heukelom S; Zweegman S; Janssen JJWM; Ossenkoppele GJ; Schuurhuis GJ; Smit L
    Cell Rep; 2018 Dec; 25(11):3021-3035.e5. PubMed ID: 30540936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding of leukemic stem cells and their clinical implications.
    Wang X; Huang S; Chen JL
    Mol Cancer; 2017 Jan; 16(1):2. PubMed ID: 28137304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.
    Iwasaki M; Liedtke M; Gentles AJ; Cleary ML
    Cell Stem Cell; 2015 Oct; 17(4):412-21. PubMed ID: 26387756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities.
    Marchand T; Pinho S
    Front Immunol; 2021; 12():775128. PubMed ID: 34721441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging drugs targeting cellular redox homeostasis to eliminate acute myeloid leukemia stem cells.
    Costa RGA; Silva SLR; Dias IRSB; Oliveira MS; Rodrigues ACBDC; Dias RB; Bezerra DP
    Redox Biol; 2023 Jun; 62():102692. PubMed ID: 37031536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress on targeting leukemia stem cells.
    Ma XY; Wei L; Lei Z; Chen Y; Ding Z; Chen ZS
    Drug Discov Today; 2021 Aug; 26(8):1904-1913. PubMed ID: 34029689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of hematopoietic and leukemic stem cells by the immune system.
    Riether C; Schürch CM; Ochsenbein AF
    Cell Death Differ; 2015 Feb; 22(2):187-98. PubMed ID: 24992931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication.
    de Leeuw DC; Denkers F; Olthof MC; Rutten AP; Pouwels W; Schuurhuis GJ; Ossenkoppele GJ; Smit L
    Cancer Res; 2014 Apr; 74(7):2094-105. PubMed ID: 24477595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.